Blood Advances Journal Citation Rate 2026
2473-9529
eISSN 2473-9537
Elsevier BV
US
Q1 Quartile Open Access Established Impact
About Blood Advances
Blood Advances (BA) is a peer-reviewed academic journal covering Acute Myeloid Leukemia Research and CAR-T cell therapy research, published by Elsevier BV in US, catalogued under ISSN 2473-9529 (e-ISSN 2473-9537). As of 2026, it has a 2025 2-Year Citation Rate (OpenAlex) of 4.44 (Q1 quartile) — the average number of citations its recent articles received over a two-year window, computed from OpenAlex open citation data, not the Clarivate (JCR) Impact Factor. It is fully open access, with an Article Processing Charge (APC) of approximately $3000 USD. OpenAlex records 6,199 works and 156,796 citations, with an h-index of 131.
Blood Advances Citation Rate 2026 — In Context
Blood Advances has a 2025 2-Year Citation Rate (OpenAlex) of 4.44, placing it in the Q1 quartile within the Acute Myeloid Leukemia Research research area. This is the average number of citations the journal's recent articles received over a two-year window, computed from OpenAlex open citation data — not the Clarivate (JCR) Journal Impact Factor.
As a fully open-access publication, Blood Advances makes all articles freely available to readers for an Article Processing Charge of approximately $3000 USD.
Researchers looking to publish in Blood Advances should review the journal's submission tips and verify the latest indexing status against Scopus, DOAJ, and Web of Science using our indexing tracker. To compare Blood Advances against similar journals in the field, use our journal comparison tool.
Submission Tips for Blood Advances
- Budget $3000 for the Article Processing Charge. Check if your institution or funder covers OA fees.
- This journal covers Acute Myeloid Leukemia Research, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research. Ensure your manuscript aligns with these scope areas to avoid desk rejection.
How Blood Advances Compares
Compared against 29 journals in the same research areas.
| ISSN (Print) | 2473-9529 |
|---|---|
| ISSN (Online) | 2473-9537 |
| Publisher | Elsevier BV |
| Country | United States |
| APC / Cost | $3000 USD |
In-depth profile & metrics
Blood Advances is published by Elsevier BV and based in United States. It publishes open access with an article-processing charge of USD 3000.
In our subject taxonomy, Blood Advances is classified under Acute Myeloid Leukemia Research, CAR-T cell therapy research, Chronic Lymphocytic Leukemia Research and Hematopoietic Stem Cell Transplantation.
Blood Advances is indexed in OpenAlex. OpenAlex tracking provides an open, citable record of its output even where commercial indexing is absent.
Its most recent citation rate stands at 4.441.
Research Areas
Links
Continue on JournalsHub
Put what you just read into practice with these free tools.
Frequently Asked Questions about Blood Advances
Live Indexing Status
Updated April 2026Track real-time indexing metrics to ensure this journal meets your academic requirements.
Citation Rate
Historical Trend
Initial data points onlyCitation Rate by Year
| Year | Value | Source |
|---|---|---|
| 2025 | 4.441 | 2-Year Mean Citedness (OpenAlex) |
Metrics are sourced from OpenAlex, DOAJ and Scopus and reflect the latest data we hold. The headline figure is a 2-year citation rate (OpenAlex), not a Clarivate Impact Factor. Always verify against the journal's official site before relying on it. See our Methodology or report a correction.
Compare Journals
Compare Blood Advances against similar publications in its field:
Related Journals in Your Field
-
Cancer Cell Elsevier IF 64.50
-
Journal for ImmunoTherapy of Cancer BMJ IF 7.57
-
Modern Pathology Elsevier BV IF 5.84
-
Leukemia Springer Nature IF 5.73
-
Molecular Therapy Elsevier BV IF 5.62
Explore More Journals
Metadata
Last updated: Apr 24, 2026
Updated by: openalex_bulk
OpenAlex ID: S2764683450
Get weekly updates for Acute Myeloid Leukemia Research journals
Free. Monday morning. New citation rates, CFPs, indexing alerts, predatory watch list. One-click unsubscribe.